Search results for "REDUCTASE"

showing 10 items of 798 documents

Genetic variants in the MTHFR are not associated with fatty liver disease.

2020

The common missense sequence variants of methylenetetrahydrofolate reductase (MTHFR), rs1801131 (c.A1298C) and rs1801133 (c.C677T), favour the development of hyperhomocysteinemia and diminished DNA methylation. Previous studies, carried out in small series and with suboptimal characterization of the hepatic phenotype, tested the association of these genetic variants with fatty liver disease (FLD), with conflicting results. Here, we assessed the association of rs1801131 and rs1801133 with hepatic phenotype in the Liver Biopsy Cross-Sectional Cohort, a large cohort (n=1375 from Italy and 411 from Finland) of European individuals with suspect FLD associated with dysmetabolism. A total of 1786 …

medicine.medical_specialtyHyperhomocysteinemiaGenotypeGastroenterologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNAFLDInternal medicinesteatosisMedicineMissense mutationHumansGenetic Predisposition to DiseaseFinlandMethylenetetrahydrofolate Reductase (NADPH2)Hepatologymedicine.diagnostic_testbiologybusiness.industryFatty liverNASHmedicine.diseaseFatty LiverCross-Sectional StudiesItaly030220 oncology & carcinogenesisLiver biopsyMethylenetetrahydrofolate reductaseCase-Control StudiesMTHFRDNA methylationCohortbiology.proteinfatty liver disease030211 gastroenterology & hepatologySteatosisfibrosibusinessLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Therapeutical approach to plasma homocysteine and cardiovascular risk reduction

2008

Marcello Ciaccio, Giulia Bivona, Chiara BelliaDepartment of Medical Biotechnologies and Forensic Medicine, Faculty of Medicine, University of Palermo, ItalyAbstract: Homocysteine is a sulfur-containing aminoacid produced during metabolism of methionine. Since 1969 the relationship between altered homocysteine metabolism and both coronary and peripheral atherotrombosis is known; in recent years experimental evidences have shown that elevated plasma levels of homocysteine are associated with an increased risk of atherosclerosis and cardiovascular ischemic events. Several mechanisms by which elevated homocysteine impairs vascular function have been proposed, including impairment of endothelial…

medicine.medical_specialtyHyperhomocysteinemiaHomocysteineReviewRM1-950folatehomocysteine MTHFR cardiovascular disease folate B vitaminchemistry.chemical_compoundcardiovascular diseaseInternal medicineMedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsEndothelial dysfunctionchemistry.chemical_classificationReactive oxygen speciesChemical Health and SafetyMethioninebiologybusiness.industryhomocysteineGeneral MedicineMetabolismmedicine.diseaseB vitaminB vitaminsEndocrinologychemistryMethylenetetrahydrofolate reductaseMTHFRbiology.proteinTherapeutics. PharmacologybusinessSafety ResearchTherapeutics and Clinical Risk Management
researchProduct

Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents

2014

Abstract Adipose tissue is an endocrine organ that secretes a number of hormones and metabolically active substances that impact energy metabolism and insulin sensitivity. These inflammatory markers are collectively referred to as adipocytokines, or adipokines. Adipose tissue's functional capacity and metabolic activity vary among individuals, thus partly explaining the incomplete overlap between obesity and the metabolic syndrome. The functional failure of adipose tissues results in changed energy delivery and impaired glucose consumption, triggering self-regulatory mechanisms to maintain homeostasis. Antihyperglycemic, hypolipidemic, antiobesity, and angiotensin II receptor blocker drugs …

medicine.medical_specialtyLipoproteinsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineAdipose tissueIncretinsNiacinAnti-Obesity AgentsInsulin resistanceAdipokinesInternal medicineInternal MedicineAnimalsHumansHypoglycemic AgentsInsulinMedicineHypolipidemic AgentsMetabolic Syndromebusiness.industryInsulinFibric AcidsEzetimibemedicine.diseaseLipidsMetforminGlucoseEndocrinologyAdipose TissueHypolipidemic AgentsAzetidinesThiazolidinedionesAnti-Obesity AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceMetabolic syndromebusinessHormoneMetabolic Syndrome and Related Disorders
researchProduct

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.

2004

Type 2 diabetes is an important cardiovascular risk factor. A significant component of the risk associated with type 2 diabetes is thought to be because of its characteristic lipid "triad" profile of raised small dense low-density lipoprotein levels, lowered high-density lipoprotein, and elevated triglycerides (TGs). Trials of statins and fibrates have included substantial numbers of patients with diabetes and indicate that lipid lowering reduces cardiovascular event rates in these patients. However, statins alone do not always address all the lipid abnormalities of diabetes. Fibrates, which have low affinity for peroxisome proliferator-activated receptor alpha (PPARalpha), improve most asp…

medicine.medical_specialtyLipoproteinsPeroxisome proliferator-activated receptorType 2 diabetesInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineLipolysisHumansPPAR alphaDyslipidemiaschemistry.chemical_classificationbusiness.industrynutritional and metabolic diseasesLipid metabolismmedicine.diseaseLipid MetabolismEndocrinologychemistryDiabetes Mellitus Type 2Cardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAmerican heart journal
researchProduct

Low-density lipoprotein size and cardiovascular risk assessment

2017

A predominance of small, dense low-density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease and evidences suggests that both quality (particularly small, dense LDL) and quantity may increase cardiovascular risk. However, other authors have suggested that LDL size measurement does not add information beyond that obtained by measuring LDL concentration, triglyceride levels and HDL concentrations. Therefore, it remains debatable whether to measure LDL particle size in cardiovascular …

medicine.medical_specialtyLow-density lipoprotein cardiovascular risk610 Medicine & health2700 General MedicineRisk Assessment142-005 142-005chemistry.chemical_compoundClofibric AcidRisk FactorsInternal medicinemedicineHumansClinical significanceRisk factorParticle SizeNational Cholesterol Education ProgramHypolipidemic AgentsTriglyceridebusiness.industryVascular diseaseAnticholesteremic AgentsConfoundingGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinologychemistryCardiovascular DiseasesLow-density lipoproteinCardiologylipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessment
researchProduct

NADPH Oxidase Accounts for Enhanced Superoxide Production and Impaired Endothelium-Dependent Smooth Muscle Relaxation in BKβ1 −/− Mice

2006

Objective— Nitric oxide (NO)-induced vasorelaxation involves activation of large conductance Ca 2+ -activated K + channels (BK). A regulatory BKβ1 subunit confers Ca 2+ , voltage, and NO/cGMP sensitivity to the BK channel. We investigated whether endothelial function and NO/cGMP signaling is affected by a deletion of the β1-subunit. Methods and Results— Vascular superoxide in BKβ1 −/− was measured using the fluorescent dye hydroethidine and lucigenin-enhanced chemiluminescence. Vascular NO formation was analyzed using electron paramagnetic resonance (EPR), expression of NADPH oxidase subunits, the endothelial NO synthase (eNOS), the soluble guanylyl cyclase (sGC), as well as the activity a…

medicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumAorta ThoracicNitric OxideMuscle Smooth VascularNitric oxideMicechemistry.chemical_compoundSuperoxidesInternal medicineCyclic GMP-Dependent Protein KinasesmedicineAnimalsHumansProtein IsoformsNADH NADPH OxidoreductasesLarge-Conductance Calcium-Activated Potassium ChannelsMice KnockoutNADPH oxidasebiologySuperoxideMicrofilament ProteinsNADPH OxidasesPhosphoproteinsMolecular biologyVasodilationEndocrinologymedicine.anatomical_structurechemistryGuanylate CyclaseNAD(P)H oxidaseNOX1ApocyninNADPH Oxidase 1biology.proteinEndothelium VascularCardiology and Cardiovascular MedicineSoluble guanylyl cyclaseCell Adhesion MoleculesSignal TransductionArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Nitric oxide synthases: regulation and function

2011

Nitric oxide (NO), the smallest signalling molecule known, is produced by three isoforms of NO synthase (NOS; EC 1.14.13.39). They all utilize l-arginine and molecular oxygen as substrates and require the cofactors reduced nicotinamide-adenine-dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydrobiopterin (BH(4)). All NOS bind calmodulin and contain haem. Neuronal NOS (nNOS, NOS I) is constitutively expressed in central and peripheral neurons and some other cell types. Its functions include synaptic plasticity in the central nervous system (CNS), central regulation of blood pressure, smooth muscle relaxation, and vasodila…

medicine.medical_specialtyNitric Oxide Synthase Type IIIEndotheliumNeovascularization PhysiologicNitric Oxide Synthase Type IIVasodilationNitric Oxide Synthase Type IReviewArginineNitric OxideEndothelial NOSNitric oxideMicechemistry.chemical_compoundEnosInternal medicineRenin–angiotensin systemmedicineAnimalsHumansbiologybusiness.industryCardiovascular AgentsGenetic Therapybiology.organism_classificationBiopterinIsoenzymesNitric oxide synthaseEndocrinologymedicine.anatomical_structurechemistryCardiovascular DiseasescGMP-specific phosphodiesterase type 5biology.proteinEndothelium VascularHydroxymethylglutaryl-CoA Reductase InhibitorsNitric Oxide SynthaseCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

Age-related changes in cholesterol metabolism in macrosomic offspring of rats with streptozotocin-induced diabetes.

2001

The aim of this study was to determine the impact of diabetic macrosomia on cholesterol and lipoprotein metabolism. Age-related changes in the activities of serum LCAT, hepatic HMG-CoA reductase, cholesterol 7α-hydroxylase, and ACAT, the major enzymes involved in cholesterol metabolism, were determined in macrosomic offspring of streptozotocin-induced diabetic rats. Hepatic, serum, and lipoprotein cholesterol contents were also examined. Mild hyperglycemia in pregnant rats was induced by intraperitoneal injection of streptozotocin (40 mg/kg body weight) on day 5 of gestation. Control pregnant rats were injected with citrate buffer. At birth, macrosomic pups had higher serum, LDL-HDL1, and H…

medicine.medical_specialtyOffspringmedicine.medical_treatmentLipoproteinsLCATIntraperitoneal injectionQD415-436GrowthReductaseBiologyBiochemistryStreptozocinDiabetes Mellitus ExperimentalFetal MacrosomiaPhosphatidylcholine-Sterol O-Acyltransferasechemistry.chemical_compoundEndocrinologyHMG-CoA reductasePregnancyInternal medicineDiabetes mellitusmedicineAnimalsmacrosomiaRats Wistarmaternal diabetesCholesterol 7-alpha-Hydroxylasecholesterol 7α-hydroxylaseCholesterolCell Biologymedicine.diseaseStreptozotocinAcetyl-CoA C-AcyltransferaseHydroxymethylglutaryl-CoA reductaseACATRatsEndocrinologyCholesterolchemistryLiverHydroxymethylglutaryl-CoA-Reductases NADP-dependentHyperglycemiaPrenatal Exposure Delayed EffectsGestationPregnancy Animallipids (amino acids peptides and proteins)FemaleHydroxymethylglutaryl CoA Reductasesmedicine.drugJournal of lipid research
researchProduct

Benign intracranial hypertension associated to blood coagulation derangements

2006

Abstract Background Benign Intracranial Hypertension (BIH) may be caused, at least in part, by intracranial sinus thrombosis. Thrombosis is normally due to derangements in blood coagulation cascade which may predispose to abnormal clotting activation or deficiency in natural inhibitors' control. The aim of the study is to examine the strength of the association between risk factors for thrombosis and BIH. Patients and methods The incidence of prothrombotic abnormalities among a randomly investigated cohort of 17 patients with BIH, was compared with 51 healthy subjects matched for sex, age, body mass index, height and social background. Results The number of subjects with protein C deficienc…

medicine.medical_specialtyPathologymedicine.medical_treatmentGastroenterologysymbols.namesakeProtein C deficiencyIntracranial hypertension blood coagulation fibrinolysisInternal medicineFibrinolysismedicineFisher's exact testAngiologyHematologybiologylcsh:RC633-647.5business.industrylcsh:Diseases of the blood and blood-forming organsHematologymedicine.diseaseThrombosisMethylenetetrahydrofolate reductasesymbolsbiology.proteinOriginal Clinical InvestigationbusinessBody mass index
researchProduct

Periodontitis, coronary heart disease and myocardial infarction: treat one, benefit all

2020

: Periodontal disease is conventionally defined as an inflammatory condition affecting the tissues surrounding and supporting the teeth (i.e. gum and periodontium). Recent statistics show that the prevalence of this condition is continuously growing worldwide, thus raising severe healthcare concerns, not only for local problems emerging from poor oral health, but also for the potential risk of developing systemic complications. Therefore, this article aims to provide an update on the intriguing association between periodontitis, coronary heart disease (CHD) and/or myocardial infarction (MI). Taken together, the available published information seems to support the existence of a significant …

medicine.medical_specialtyPeriodontitis coronary heart disease myocardial infarctionCoronary Artery Disease030204 cardiovascular system & hematologyOverweightCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineAnimalsHumansMyocardial infarctionEndothelial dysfunctioncoronary heart diseasePeriodontitisPeriodontitisbusiness.industryHematologyGeneral MedicinePeriodontiummedicine.diseaseCoronary heart diseaseTreatment Outcomemyocardial infarctionmedicine.symptomHydroxymethylglutaryl-CoA Reductase Inhibitorsbusiness030215 immunology
researchProduct